41 results
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
22 Jun 23
Globestar Therapeutics Enters into Mou with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment
5:18pm
Exhibit 99.1
GLOBESTAR THERAPEUTICS ENTERS INTO MOU WITH ADVANCED INNOVATIVE PARTNERS TO DEVELOP CLINICAL STUDIES FOR MULTIPLE SCLEROSIS TREATMENT … focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, and Advanced Innovative Partners (AIP), a clinical-stage
S-1/A
GSTC
GlobeStar Therapeutics Corp
28 Dec 10
IPO registration (amended)
12:00am
and wiring harnesses that we intend to sell.
Business Strategy, page 21
We note your disclosure that there is a “strong need for a new innovative approach … in the design and manufacturing of industrial panels and wire harnesses…”. Please revise to clarify how your business plan would be an innovative
8-K
GSTC
GlobeStar Therapeutics Corp
13 Nov 23
Other Events
12:32pm
Sclerosis (MS) and other neurological diseases has entered into a definitive agreement with Advanced Innovative Partners (AIP) for AIP to provide advice … Innovative Partners dated November 2, 2023
Collaboration Agreement with SMI HealthCare LLC dated September 26, 2023
Cover Page Interactive Data File
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
15 May 18
Regulation FD Disclosure
3:17pm
://www.angiosoma.com), a Nevada corporation based in Houston, Texas, markets our SomaceuticalsTM line of health supplements. Our innovative supplements
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
12 Oct 21
Regulation FD Disclosure
8:27am
Corporation.
GlobeStar Therapeutics Corporation (OTCQB: GSTC) is a healthcare company dedicated to bringing innovative, effective, and high-quality healthcare
8-K
EX-99
0kzodtfkmo1s7knm
19 Jun 18
AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug
11:56am
8-K
EX-99
9gqf3usu
9 Dec 20
SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis
12:00am
8-K
EX-99
hfm6e stk
25 Feb 21
Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent
5:30pm
8-K
EX-99
8m6xr
24 Aug 20
SomaCeuticals Acquires License for Treatment of Multiple Sclerosis
5:01pm
8-K
EX-99
tjozjyv7u3 tt6x
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
8-K
EX-99
p625 23wd0bu9swi0tjl
4 Oct 21
Regulation FD Disclosure
8:48am
8-K
EX-99
2voqsfaguoo8jbl2a
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
8-K
EX-99
8kico7i5y8c844n95x
16 Apr 21
AngioSoma, Inc. Is Pleased to Welcome William Farley to Its Board of Directors
4:20pm
8-K
EX-99
i1cfej1 bd
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
8-K
86kdgq5 i34
22 Jun 23
Globestar Therapeutics Enters into Mou with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment
5:18pm
8-K
EX-99
g3box mes
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm